Prevalence of humeral head osteochondrosis in the Greater Swiss Mountain dog and the Border Collie in Switzerland.

INTRODUCTION: Osteochondrosis (OC) is common in large-breed dogs. According to the breeding guidelines of the Swiss kennel clubs, the shoulder joints are included in the radiographic screening for joint diseases in the Greater Swiss Mountain dog (GSMD) and the Border Collie (BC) since 1993 and 2003, respectively. The aim of this study was to estimate the overall prevalence of humeral head OC in these 2 breeds in Switzerland based on the data of the Swiss National Dysplasia Committees. All radiographs were re-evaluated to assess single radiographic changes. From 1993 and 2003, accordingly, until 2013, the overall prevalence was 14% for the GSMD and 8% for the BC, respectively. Affected joints showed a focally reduced opacity or a flattened/indented contour of the caudal section of the humeral head. Articular flaps were only seen occasionally. Degenerative joint disease was significantly more common in OC affected joints (GSMD: 32%; BC: 20%) than in joints without OC. The present study is the first report on the prevalence of humeral head OC in a large cohort of GSMD and the BC over a long study period. In comparison to other breeds, the herein reported prevalences are in the mid to upper range. Results of the present study should alert veterinarians to the disease in these breeds and may serve as a starting point for further epidemiological and genetic studies.

INTRODUCTION: L'ostéochondrose (OC) est fréquente chez les chiens de grande race. Conformément aux prescriptions d'élevage des clubs cynologiques suisses, l'articulation de l'épaule est incluse dans le dépistage radiologique des affections articulaires chez le Grand bouvier suisse (GBS) et le Border Collie (BC) et ceci depuis 1993 respectivement 2003. Le but de la présente étude était d'estimer la prévalence de l'OC de la tête humérale chez ces deux races en Suisse, sur la base des données des commissions nationales suisses de dysplasie. Toutes les radiographies ont été réévaluées pour repérer des altérations radiologiques isolées. Depuis 1993 respectivement 2003 jusqu'en 2013, la prévalence était de 14% chez le GBC et de 8% chez le BC. Les articulations affectées montraient une opacité localement réduite ou un contour aplati/ dentelé de la partie caudale de la tête humérale. Des souris articulaires n'étaient constatées qu'occasionnellement. Les affections articulaires dégénératives étaient significativement plus fréquentes sur les articulations affectées d'OC que sur les autres (GBS: 32%; BC: 20%). La présente étude rapporte pour la première fois la prévalence de l'OC de la tête humérale sur une large cohorte de GBS et de BC sur une longue période. En comparaison avec d'autres races, les prévalences constatées se situent entre la moyenne et le niveau supérieur. Les résultats de cette étude doivent alerter les vétérinaires au sujet de cette affection chez ces races et peut server de pont de départ pour de futures recherches épidémiologiques et génétiques.

Statisticians and pharmacokineticists: what they can still learn from each other.

Examples are given of how the practice of statistics could be improved if statisticians showed a greater awareness of pharmacokinetic and pharmacodynamic modeling. Some examples are also given where a wider appreciation of statistical theory would improve current approaches to pharmacometrics. Areas in which the two disciplines are in agreement but have failed to have as much influence on others in drug development as they ought are also considered. It is concluded that there would be much benefit in increasing collaboration between these disciplines.

Ethical considerations concerning treatment allocation in drug development trials.

It is claimed that much of the opposition to placebos is based on the misunderstanding that their use implies the withholding of effective treatments. It is also argued that the ethical feasibility of a trial must be judged by comparing the likely prognosis of patients in the trial to their expectations outside the trial. Furthermore, a longer-term perspective of the patients needs is necessary; the ethical dilemmas involved cannot be resolved at the point of sickness. Some device such as the 'original position' of the philosopher John Rawls is needed. Finally, it is argued that placebo run-ins involve a violation of consent and should be eliminated from clinical trials.

Actions other than smooth muscle relaxation may play a role in the protective effects of formoterol on the allergen-induced late asthmatic reaction.

Long-acting beta(2)-adrenoceptor agonists attenuate the allergen-induced late asthmatic reaction. We evaluated whether other mechanisms in addition to airway smooth muscle relaxation may be implicated in this protective effect. The effects of formoterol (Foradil Aerolizer(TM), 24 microg dry powder) on the late asthmatic reaction were assessed by a randomised crossover factorial study in 24 patients with asthma. Four challenge/treatment combinations were tested: (A) saline/placebo, (B) saline/formoterol, (C) allergen/placebo, (D) allergen/formoterol. Formoterol and placebo were administered double blind after the last inhalation of the allergen or saline. FEV(1) was measured up to 32 h. The bronchodilator effect of formoterol was estimated as (B-A) and the overall protective effect as (D-C). The effect not due to bronchodilation was estimated as [(D-C)-(B-A)]/2. The bronchodilator effect of formoterol was statistically significant up to 5h (all P< or =0.015). Formoterol significantly attenuated the late asthmatic reaction between 3 and 32 h after allergen inhalation (all P< or =0.0012). The difference between this protective effect and the bronchodilator effect was statistically significant at 5 h and between 7 and 28 h after allergen inhalation (all P< or =0.035). Our results suggest that functional antagonism may not be the sole mechanism by which formoterol attenuates the allergen-induced late asthmatic reaction.

Statistical issues in bioequivalence [correction of bioequivalance].

There has been much work recently on individual bioequivalence and the topic has attracted considerable controversy. Some previous controversies regarding average bioequivalence are examined. It is argued that a contributory factor in these controversies may have been confusion over the purpose of bioequivalence trials. It is concluded that this purpose needs further clarification before guidelines for individual bioequivalence can be established and indeed that such guidelines may turn out to be unnecessary.

Two cheers for P-values?

P-values are a practical success but a critical failure. Scientists the world over use them, but scarcely a statistician can be found to defend them. Bayesians in particular find them ridiculous, but even the modern frequentist has little time for them. In this essay, I consider what, if anything, might be said in their favour.

Surveillance of antimicrobial resistance--what, how and whither?

OBJECTIVE: To express the views of a working party held to consider antibiotic resistance surveillance systems, their strengths and weaknesses, and their current and future applications. METHODS: The participants, all of whom were experienced in this field, discussed the development of surveillance systems in relation to the increasing prevalence of resistance to antibacterial agents and the current interest in surveillance systems shown by many official bodies, in both the human and veterinary fields. The problems inherent in surveillance systems were considered together with the applications of different systems. RESULTS: The properties of good antibiotic resistance surveillance systems were defined. Surveillance systems vary widely from those with a narrow base, focusing on few organisms in one disease area, to those covering many diseases, many organisms (including normal flora) and many compounds. Whatever their design, they should be able to detect significant differences and shifts in susceptibility to various antibacterial agents, and the information derived from them should reach as many interested parties as possible in a timely manner. In using this information to decide strategies, criteria for action need to be determined by pragmatic consensus. Funding remains a major problem, with few large studies being supported by official bodies in spite of their professed enthusiasm for surveillance. In consequence, many current systems are funded by the pharmaceutical industry and are of necessity restricted in their focus. CONCLUSIONS: Antibiotic resistance surveillance studies should and can be well planned and well executed. Many current systems suffer from well-recognized but uncorrected biases. Consortium funding will be necessary for large schemes to be successful. There is no "ideal" surveillance system.

Repeated measures in clinical trials: simple strategies for analysis using summary measures.

The summary measures approach to analysing repeated measures is described. The circumstances under which it can be advantageous to use such measures are considered. Strategies for baseline adjustment where there are multiple baselines are examined, as is the choice of appropriate summary statistic. A compromise trend/mean measure, regression through the origin, is proposed as being useful under some circumstances. An analysis using this measure is illustrated with a suitable example.